<DOC>
	<DOC>NCT00007033</DOC>
	<brief_summary>OBJECTIVES: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.</brief_summary>
	<brief_title>Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive magnesium sulfate IV over 1 hour on day 3. Patients then receive oral magnesium gluconate supplementation daily. Treatment with magnesium sulfate repeats once at 3-6 months.</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Biliary Atresia</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Diagnosis of liver disease with chronic cholestasis Nonsyndromic intrahepatic cholestasis Alagille's syndrome Extrahepatic biliary atresia Direct bilirubin greater than 2 mg/dL OR Bile acids greater than 20 micromoles/L No hepatic decompensation defined as one or more of the following: Ascites Peripheral edema PT at least 4 seconds longer than control Albumin less than 3 g/dL Patient Characteristics Renal: No significant renal disease Cardiovascular: No significant cardiovascular disease Pulmonary: No significant pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>Alagille syndrome</keyword>
	<keyword>biliary atresia</keyword>
	<keyword>cholestasis</keyword>
	<keyword>gastrointestinal disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>